van Lingen R A, Deinum H T, Quak C M, Okken A, Tibboel D
Department of Pediatrics, Isala Clinics/Sophia Hospital, Zwolle, The Netherlands.
Clin Pharmacol Ther. 1999 Nov;66(5):509-15. doi: 10.1016/S0009-9236(99)70014-7.
To investigate pharmacokinetics and pharmacodynamics of rectally administered acetaminophen (INN, paracetamol) in term neonates directly after birth.
In this prospective clinical trial, term neonates wtih painful conditions or who were undergoing painful procedures received multiple-dose acetaminophen. Serum concentrations were determined serially with an HPLC method, and pharmacokinetic analysis was performed. Pain assessment was performed by means of a validated pain score.
Ten consecutive term neonates received four rectal doses of acetaminophen, 20 mg/kg body weight, every 6 hours. Mean peak serum concentrations (+/-SD) during multiple-dose administration were 10.79 +/- 6.39 mg/L, 15.34 +/- 5.21 mg/L, and 6.24 +/- 3.64 mg/L for the entire group, boys, and girls, respectively. There was a significant difference between the boys and the girls (P = .01). No serum concentrations associated with toxicity (>120 mg/L) were found. Median time to peak serum concentration was 1.5 hours after the first dose and 15 hours for multiple doses. Mean (+/-SD) half-life was 2.7 +/- 1.4 hours in eight patients. There was no correlation between dose and serum concentration or between pain score and serum concentration. There was a significant inverse relationship between the preceding pain score and peak serum concentrations.
In term neonates, multiple rectal doses of acetaminophen, 20 mg/kg body weight, led to widely varying serum concentrations but did not result in therapeutic concentrations in all infants. Boys had higher peak concentrations. Because accumulation was not found, a dose of 30 mg/kg followed by doses of 20 mg/kg at 6- to 8-hour administration intervals are appropriate to reach therapeutic concentrations. A concentration-effect relationship could not be determined.
研究出生后即刻经直肠给予对乙酰氨基酚(国际非专利药品名称,扑热息痛)在足月儿中的药代动力学和药效学。
在这项前瞻性临床试验中,患有疼痛性疾病或正在接受疼痛性操作的足月儿接受多剂量对乙酰氨基酚治疗。采用高效液相色谱法连续测定血清浓度,并进行药代动力学分析。通过有效的疼痛评分进行疼痛评估。
10例连续的足月儿每6小时接受4次直肠给予的对乙酰氨基酚,剂量为20mg/kg体重。多剂量给药期间,全组、男孩和女孩的平均血清峰值浓度(±标准差)分别为10.79±6.39mg/L、15.34±5.21mg/L和6.24±3.64mg/L。男孩和女孩之间存在显著差异(P = 0.01)。未发现与毒性相关的血清浓度(>120mg/L)。血清峰值浓度的中位时间在首剂后为1.5小时,多剂给药后为15小时。8例患者的平均(±标准差)半衰期为2.7±1.4小时。剂量与血清浓度之间或疼痛评分与血清浓度之间均无相关性。先前的疼痛评分与血清峰值浓度之间存在显著的负相关关系。
在足月儿中,每6小时直肠给予20mg/kg体重的多剂量对乙酰氨基酚导致血清浓度差异很大,但并非所有婴儿都能达到治疗浓度。男孩的峰值浓度更高。由于未发现蓄积现象,给予30mg/kg的首剂,随后以6至8小时间隔给予20mg/kg的剂量,适宜达到治疗浓度。无法确定浓度-效应关系。